PPLPHARMA NSE filing

Piramal Pharma: Audio Recording of Q4 FY26 Results Conference Call Available

The RealCase readLow impact Neutral

Piramal Pharma Limited has released the audio recording of its conference call discussing the audited financial results for the quarter and year ended March 31, 2026. The recording is available on the company's website.

Why it matters

This is a procedural update providing access to previously discussed financial results, and it does not introduce new material information that would significantly impact the company's stock or market position.

The market read

The announcement is a routine update regarding the availability of a conference call recording for financial results and does not contain new financial information or significant strategic developments.

Piramal Pharma Limited (PPL) has announced that the audio recording of the conference call held on 29th April, 2026, is now available on the company's website. This call discussed the audited financial results, both standalone and consolidated, for the quarter and year ended 31st March, 2026.

The company previously informed the exchanges about this conference call on 17th April, 2026. The recording can be accessed on the 'Financial Reports' section of the Piramal Pharma website at https://www.piramalpharma.com/financial-reports.

This announcement is made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Filing to action

What to do with a filing like this

Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.

View original filing